Calcium channel blocker exposure and psoriasis risk: Pharmacovigilance investigation and literature data

Evidence regarding a possible association between psoriatic manifestations and use of calcium channel blockers (CCBs) is sparse. Currently, psoriatic manifestations are not listed in the summary of product characteristics (SmPC) of CCBs. In this context, we aimed to investigate the association between psoriasis and CCB exposure. We reviewed spontaneous reports recorded in the French national pharmacovigilance database (FPVD) between 1985 and...